Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.57
JNJ's Cash-to-Debt is ranked lower than
66% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. JNJ: 0.57 )
Ranked among companies with meaningful Cash-to-Debt only.
JNJ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.22 Max: 6.28
Current: 0.57
0.15
6.28
Equity-to-Asset 0.41
JNJ's Equity-to-Asset is ranked lower than
78% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. JNJ: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
JNJ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38  Med: 0.54 Max: 0.67
Current: 0.41
0.38
0.67
Debt-to-Equity 0.51
JNJ's Debt-to-Equity is ranked lower than
63% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. JNJ: 0.51 )
Ranked among companies with meaningful Debt-to-Equity only.
JNJ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06  Med: 0.26 Max: 0.58
Current: 0.51
0.06
0.58
Debt-to-EBITDA 1.24
JNJ's Debt-to-EBITDA is ranked higher than
62% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. JNJ: 1.24 )
Ranked among companies with meaningful Debt-to-EBITDA only.
JNJ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.59  Med: 0.87 Max: 1.43
Current: 1.24
0.59
1.43
Interest Coverage 18.63
JNJ's Interest Coverage is ranked lower than
63% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. JNJ: 18.63 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 18.63  Med: 34.53 Max: 39.32
Current: 18.63
18.63
39.32
Piotroski F-Score: 7
Altman Z-Score: 4.50
Beneish M-Score: -3.06
WACC vs ROIC
5.89%
1.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 23.44
JNJ's Operating Margin % is ranked higher than
87% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. JNJ: 23.44 )
Ranked among companies with meaningful Operating Margin % only.
JNJ' s Operating Margin % Range Over the Past 10 Years
Min: 23.44  Med: 25.78 Max: 29.4
Current: 23.44
23.44
29.4
Net Margin % 1.70
JNJ's Net Margin % is ranked lower than
63% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. JNJ: 1.70 )
Ranked among companies with meaningful Net Margin % only.
JNJ' s Net Margin % Range Over the Past 10 Years
Min: 1.7  Med: 20.07 Max: 23.01
Current: 1.7
1.7
23.01
ROE % 2.06
JNJ's ROE % is ranked lower than
61% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. JNJ: 2.06 )
Ranked among companies with meaningful ROE % only.
JNJ' s ROE % Range Over the Past 10 Years
Min: 1.99  Med: 22.29 Max: 30.17
Current: 2.06
1.99
30.17
ROA % 0.88
JNJ's ROA % is ranked lower than
60% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. JNJ: 0.88 )
Ranked among companies with meaningful ROA % only.
JNJ' s ROA % Range Over the Past 10 Years
Min: 0.87  Med: 11.87 Max: 15.61
Current: 0.88
0.87
15.61
ROC (Joel Greenblatt) % 98.03
JNJ's ROC (Joel Greenblatt) % is ranked higher than
96% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. JNJ: 98.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
JNJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 65.66  Med: 93.44 Max: 119.25
Current: 98.03
65.66
119.25
3-Year Revenue Growth Rate 2.40
JNJ's 3-Year Revenue Growth Rate is ranked lower than
63% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. JNJ: 2.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
JNJ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 8.8 Max: 14.8
Current: 2.4
1.3
14.8
3-Year EBITDA Growth Rate 0.40
JNJ's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. JNJ: 0.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
JNJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 9.8 Max: 19.3
Current: 0.4
-6.6
19.3
3-Year EPS without NRI Growth Rate -56.50
JNJ's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. JNJ: -56.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
JNJ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.5  Med: 12.4 Max: 34.2
Current: -56.5
-56.5
34.2
GuruFocus has detected 6 Warning Signs with Johnson & Johnson JNJ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» JNJ's 30-Y Financials

Financials (Next Earnings Date: 2018-10-17)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

JNJ Guru Trades in Q3 2017

Louis Moore Bacon 20,000 sh (New)
Caxton Associates 5,400 sh (New)
Paul Tudor Jones 38,969 sh (+1056.01%)
Joel Greenblatt 80,883 sh (+224.40%)
Lee Ainslie 39,900 sh (+32.56%)
John Rogers 989,289 sh (+4.09%)
Steven Cohen 689,342 sh (+3.03%)
Ken Fisher 11,797,674 sh (+2.59%)
Murray Stahl 24,618 sh (+1.70%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Focused Fund 1,600,000 sh (unchged)
Yacktman Fund 3,100,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
David Carlson 460,000 sh (unchged)
First Eagle Investment 26,921 sh (unchged)
Richard Snow 3,215 sh (unchged)
Prem Watsa 151,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,750 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 347,253 sh (unchged)
Richard Pzena Sold Out
Michael Price Sold Out
Tweedy Browne 2,292,554 sh (-0.28%)
Yacktman Asset Management 5,653,623 sh (-0.38%)
Jeff Auxier 102,851 sh (-0.53%)
Mairs and Power 2,209,403 sh (-0.72%)
John Buckingham 64,847 sh (-1.45%)
PRIMECAP Management 924,225 sh (-1.88%)
Pioneer Investments 2,223,833 sh (-2.00%)
Manning & Napier Advisors, Inc 1,778,271 sh (-2.96%)
Mario Gabelli 247,675 sh (-3.36%)
T Rowe Price Equity Income Fund 3,230,000 sh (-7.60%)
Dodge & Cox 30,514 sh (-8.02%)
Jeremy Grantham 4,564,838 sh (-9.61%)
Barrow, Hanley, Mewhinney & Strauss 10,607,089 sh (-14.27%)
Diamond Hill Capital 1,733 sh (-20.65%)
Jim Simons 4,306,200 sh (-29.78%)
Charles Brandes 58,510 sh (-52.14%)
» More
Q4 2017

JNJ Guru Trades in Q4 2017

First Pacific Advisors 9,700 sh (New)
Tom Russo 1,315 sh (New)
Joel Greenblatt 239,967 sh (+196.68%)
Pioneer Investments 4,719,253 sh (+112.21%)
Caxton Associates 11,177 sh (+106.98%)
Lee Ainslie 67,520 sh (+69.22%)
Diamond Hill Capital 1,909 sh (+10.16%)
Ken Fisher 12,127,379 sh (+2.79%)
John Rogers 1,012,823 sh (+2.38%)
Tweedy Browne Global Value 865,835 sh (unchged)
David Carlson 460,000 sh (unchged)
First Eagle Investment 26,921 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Richard Snow 3,215 sh (unchged)
Prem Watsa 151,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 347,253 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 921,323 sh (-0.31%)
Murray Stahl 24,518 sh (-0.41%)
Mairs and Power 2,191,819 sh (-0.80%)
Dodge & Cox 30,240 sh (-0.90%)
Tweedy Browne 2,248,251 sh (-1.93%)
Jeff Auxier 100,455 sh (-2.33%)
John Buckingham 62,884 sh (-3.03%)
David Rolfe 5,550 sh (-3.48%)
T Rowe Price Equity Income Fund 3,100,000 sh (-4.02%)
Jeremy Grantham 4,319,219 sh (-5.38%)
Barrow, Hanley, Mewhinney & Strauss 10,028,494 sh (-5.45%)
Charles Brandes 55,046 sh (-5.92%)
Yacktman Fund 2,900,000 sh (-6.45%)
Yacktman Asset Management 5,186,544 sh (-8.26%)
Yacktman Focused Fund 1,450,000 sh (-9.38%)
Mario Gabelli 207,376 sh (-16.27%)
Jim Simons 3,469,800 sh (-19.42%)
Steven Cohen 46,900 sh (-93.20%)
» More
Q1 2018

JNJ Guru Trades in Q1 2018

Paul Tudor Jones 45,103 sh (New)
Signature Select Canadian Fund 49,900 sh (New)
Steven Cohen 388,716 sh (+728.82%)
Joel Greenblatt 390,826 sh (+62.87%)
Lee Ainslie 98,820 sh (+46.36%)
Tom Russo 1,715 sh (+30.42%)
Jeremy Grantham 4,941,803 sh (+14.41%)
First Pacific Advisors 10,400 sh (+7.22%)
Ken Fisher 12,639,622 sh (+4.22%)
Mairs and Power 2,221,696 sh (+1.36%)
Eaton Vance Worldwide Health Sciences Fund 496,664 sh (+43.03%)
Yacktman Fund 2,900,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Tom Gayner 610,800 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Snow 3,215 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,550 sh (unchged)
Steven Cohen 50,000 sh (unchged)
First Eagle Investment Sold Out
Yacktman Asset Management 5,173,615 sh (-0.25%)
Murray Stahl 24,457 sh (-0.25%)
Jeff Auxier 100,030 sh (-0.42%)
Dodge & Cox 29,990 sh (-0.83%)
Tweedy Browne 2,221,515 sh (-1.19%)
PRIMECAP Management 909,475 sh (-1.29%)
Yacktman Focused Fund 1,430,000 sh (-1.38%)
Prem Watsa 148,650 sh (-1.72%)
John Rogers 987,940 sh (-2.46%)
T Rowe Price Equity Income Fund 2,980,000 sh (-3.87%)
Diamond Hill Capital 1,831 sh (-4.09%)
John Buckingham 60,066 sh (-4.48%)
Caxton Associates 10,527 sh (-5.82%)
Barrow, Hanley, Mewhinney & Strauss 9,435,767 sh (-5.91%)
Charles Brandes 51,706 sh (-6.07%)
Mario Gabelli 190,751 sh (-8.02%)
Pioneer Investments 4,129,368 sh (-12.50%)
Jim Simons 1,284,399 sh (-62.98%)
» More
Q2 2018

JNJ Guru Trades in Q2 2018

Ray Dalio 109,950 sh (New)
Jim Simons 3,740,300 sh (+191.21%)
Pioneer Investments 4,524,003 sh (+9.56%)
David Rolfe 6,050 sh (+9.01%)
Steven Cohen 416,400 sh (+7.12%)
Joel Greenblatt 414,164 sh (+5.97%)
Charles Brandes 54,647 sh (+5.69%)
Ken Fisher 13,118,604 sh (+3.79%)
Caxton Associates 10,704 sh (+1.68%)
John Rogers 1,002,162 sh (+1.44%)
T Rowe Price Equity Income Fund 3,020,000 sh (+1.34%)
Diamond Hill Capital 1,853 sh (+1.20%)
Yacktman Fund 2,900,000 sh (unchged)
Yacktman Focused Fund 1,430,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Richard Snow 3,215 sh (unchged)
Tom Russo 1,715 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Dodge & Cox 29,990 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 496,664 sh (unchged)
First Pacific Advisors Sold Out
Mairs and Power 2,207,186 sh (-0.65%)
Tweedy Browne Global Value 860,002 sh (-0.67%)
Jeff Auxier 99,360 sh (-0.67%)
Yacktman Asset Management 5,128,961 sh (-0.86%)
Murray Stahl 24,233 sh (-0.92%)
John Buckingham 59,357 sh (-1.18%)
Prem Watsa 146,800 sh (-1.24%)
Tweedy Browne 2,177,149 sh (-2.00%)
Mario Gabelli 183,094 sh (-4.01%)
Barrow, Hanley, Mewhinney & Strauss 8,957,593 sh (-5.07%)
Lee Ainslie 73,820 sh (-25.30%)
Jeremy Grantham 3,627,489 sh (-26.60%)
PRIMECAP Management 535,700 sh (-41.10%)
Paul Tudor Jones 18,120 sh (-59.83%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Add 3.79%0.08%$119.4 - $131.76 $ 141.0913%13,118,604
Barrow, Hanley, Mewhinney & Strauss 2018-06-30 Reduce -5.07%0.1%$119.4 - $131.76 $ 141.0913%8,957,593
Yacktman Asset Management 2018-06-30 Reduce -0.86%0.06%$119.4 - $131.76 $ 141.0913%5,128,961
T Rowe Price Equity Income Fund 2018-06-30 Add 1.34%0.02%$119.4 - $131.76 $ 141.0913%3,020,000
Tweedy Browne 2018-06-30 Reduce -2.00%0.17%$119.4 - $131.76 $ 141.0913%2,177,149
John Rogers 2018-06-30 Add 1.44%0.02%$119.4 - $131.76 $ 141.0913%1,002,162
Joel Greenblatt 2018-06-30 Add 5.97%0.04%$119.4 - $131.76 $ 141.0913%414,164
Mario Gabelli 2018-06-30 Reduce -4.01%0.01%$119.4 - $131.76 $ 141.0913%183,094
Prem Watsa 2018-06-30 Reduce -1.24%0.02%$119.4 - $131.76 $ 141.0913%146,800
Charles Brandes 2018-06-30 Add 5.69%0.01%$119.4 - $131.76 $ 141.0913%54,647
Ken Fisher 2018-03-31 Add 4.22%0.09%$125.1 - $148.14 $ 141.094%12,639,622
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Reduce -5.91%0.12%$125.1 - $148.14 $ 141.094%9,435,767
Yacktman Asset Management 2018-03-31 Reduce -0.25%0.02%$125.1 - $148.14 $ 141.094%5,173,615
T Rowe Price Equity Income Fund 2018-03-31 Reduce -3.87%0.08%$125.1 - $148.14 $ 141.094%2,980,000
Tweedy Browne 2018-03-31 Reduce -1.19%0.1%$125.1 - $148.14 $ 141.094%2,221,515
Yacktman Focused Fund 2018-03-31 Reduce -1.38%0.09%$125.1 - $148.14 $ 141.094%1,430,000
John Rogers 2018-03-31 Reduce -2.46%0.04%$125.1 - $148.14 $ 141.094%987,940
Joel Greenblatt 2018-03-31 Add 62.87%0.27%$125.1 - $148.14 $ 141.094%390,826
Mario Gabelli 2018-03-31 Reduce -8.02%0.01%$125.1 - $148.14 $ 141.094%190,751
Prem Watsa 2018-03-31 Reduce -1.72%0.03%$125.1 - $148.14 $ 141.094%148,650
Charles Brandes 2018-03-31 Reduce -6.07%0.01%$125.1 - $148.14 $ 141.094%51,706
Dodge & Cox 2018-03-31 Reduce -0.83%$125.1 - $148.14 $ 141.094%29,990
First Eagle Investment 2018-03-31 Sold Out 0.01%$125.1 - $148.14 $ 141.094%0
Ken Fisher 2017-12-31 Add 2.79%0.06%$131.22 - $143.62 $ 141.091%12,127,379
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -5.45%0.11%$131.22 - $143.62 $ 141.091%10,028,494
Yacktman Asset Management 2017-12-31 Reduce -8.26%0.59%$131.22 - $143.62 $ 141.091%5,186,544
T Rowe Price Equity Income Fund 2017-12-31 Reduce -4.02%0.08%$131.22 - $143.62 $ 141.091%3,100,000
Yacktman Fund 2017-12-31 Reduce -6.45%0.41%$131.22 - $143.62 $ 141.091%2,900,000
Tweedy Browne 2017-12-31 Reduce -1.93%0.16%$131.22 - $143.62 $ 141.091%2,248,251
Yacktman Focused Fund 2017-12-31 Reduce -9.38%0.61%$131.22 - $143.62 $ 141.091%1,450,000
John Rogers 2017-12-31 Add 2.38%0.04%$131.22 - $143.62 $ 141.091%1,012,823
Joel Greenblatt 2017-12-31 Add 196.68%0.32%$131.22 - $143.62 $ 141.091%239,967
Mario Gabelli 2017-12-31 Reduce -16.27%0.03%$131.22 - $143.62 $ 141.091%207,376
Charles Brandes 2017-12-31 Reduce -5.92%0.01%$131.22 - $143.62 $ 141.091%55,046
Dodge & Cox 2017-12-31 Reduce -0.90%$131.22 - $143.62 $ 141.091%30,240
Ken Fisher 2017-09-30 Add 2.59%0.06%$129.47 - $136.57 $ 141.096%11,797,674
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -14.27%0.36%$129.47 - $136.57 $ 141.096%10,607,089
Yacktman Asset Management 2017-09-30 Reduce -0.38%0.03%$129.47 - $136.57 $ 141.096%5,653,623
T Rowe Price Equity Income Fund 2017-09-30 Reduce -7.60%0.16%$129.47 - $136.57 $ 141.096%3,230,000
Tweedy Browne 2017-09-30 Reduce -0.28%0.03%$129.47 - $136.57 $ 141.096%2,292,554
John Rogers 2017-09-30 Add 4.09%0.06%$129.47 - $136.57 $ 141.096%989,289
Mario Gabelli 2017-09-30 Reduce -3.36%0.01%$129.47 - $136.57 $ 141.096%247,675
Joel Greenblatt 2017-09-30 Add 224.40%0.1%$129.47 - $136.57 $ 141.096%80,883
Charles Brandes 2017-09-30 Reduce -52.14%0.14%$129.47 - $136.57 $ 141.096%58,510
Dodge & Cox 2017-09-30 Reduce -8.02%$129.47 - $136.57 $ 141.096%30,514
Richard Pzena 2017-09-30 Sold Out 0.53%$129.47 - $136.57 $ 141.096%0
Michael Price 2017-09-30 Sold Out 0.09%$129.47 - $136.57 $ 141.096%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, XSWX:ROG, XSWX:NOVN, NYSE:MRK, NYSE:ABBV, XTER:BAYN, LSE:GSK, XPAR:SAN, NYSE:LLY, LSE:AZN, NYSE:BMY, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867 » details
Traded in other countries:JNJ.Argentina, JNJ.Austria, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Headquarter Location:USA
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. Close to half of total revenue is generated within the United States.

Guru Investment Theses on Johnson & Johnson

Yacktman Fund Comments on Johnson & Johnson - Aug 09, 2018

J&J (NYSE:JNJ) declined in the second quarter after delivering strong returns in 2016 and 2017. It faces generic challenges to some of its major pharmaceuticals, but we believe J&J is well diversified and positioned to provide solid growth over time.





From Yacktman Fund (Trades, Portfolio)'s 2nd quarter 2018 shareholder letter.

Check out Donald Yacktman,Yacktman Asset Management latest stock trades

Jeff Auxier Comments on Johnson & Johnson - Aug 09, 2018

Johnson & Johnson (NYSE:JNJ)



One of only 22 companies to increase dividends every year for at least 50 consecutive years, Johnson & Johnson increased total sales in the first quarter 12.6% to over $20 billion. As the world’s largest medical conglomerate, they are well positioned to provide medicine and care for aging Baby Boomers.

From Jeff Auxier (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Johnson & Johnson - May 07, 2018

Johnson & Johnson (NYSE:JNJ)



Despite beating Wall Street’s fourth quarter earnings and revenue expectations, Johnson & Johnson lost investor confidence on a projected 2018 operational revenue growth of 3.5% to 4.5%. J&J’s $30B acquisition of Actelion last summer contributed 4.2% towards their Worldwide Pharmaceutical sales growth of 8.4% to $36.3B in the quarter.





From Jeff Auxier (Trades, Portfolio)'s first-quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Johnson & Johnson - Feb 06, 2018

Johnson & Johnson (NYSE:JNJ) saw a 10.3% growth in net sales as their Pharmaceutical segment–which represents 49% of overall sales–jumped 15% in the quarter. This has been due in part to the consistently growing sales of their lymphoma treatment, Imbruvica, increasing 46.7% year over year as additional implications continue to be approved by the FDA.







From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Johnson & Johnson - Aug 03, 2017

AAA rated Johnson & Johnson (NYSE:JNJ) is the world’s largest medical conglomerate. Johnson & Johnson just completed the acquisition of Actelion which gives them a sixth therapeutic area to address potential patients with pulmonary arterial hypertension. Johnson & Johnson expects the acquisition of Actelion to add $1.3 billion in sales for 2017.




From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Ariel Funds Comments on Johnson & Johnson - Sep 28, 2016

Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward.



From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Johnson & Johnson

Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Richard Snow Slashes Lannett Stake by 85% Pharmaceutical company recently lost major supplier
Snow Capital Management leader Richard Snow (Trades, Portfolio) disclosed this week that he reduced his Lannett Co. Inc. (NYSE:LCI) position by 84.76% on Aug. 21. Read more...
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
UPDATE: Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
Johnson & Johnson to Participate in the 2018 Morgan Stanley 16th Annual Global Healthcare Conference
Johnson & Johnson to Host Investor Conference Call on the Phase 3 MARINER and COMMANDER HF Studies for XARELTO®
Caldwell Cassady & Curry Helps Acantha Win $8.2 Million Patent Infringement Verdict Against Medical Device Giant DePuy Synthes
US Market Indexes Continue Gains on Monday Dow Jones closes at 25,758.69 with a gain of 0.35%
The Dow Jones Industrial Average closed at 25,758.69 on Monday with a gain of 89.37 points or 0.35%. The S&P 500 closed at 2,857.05 for a gain of 6.92 points or 0.24%. The Nasdaq Composite closed at 7,821.01 for a gain of 4.68 points or 0.06%. The VIX Volatility Index was lower at 12.49 for a loss of -0.15 points or -1.19%. Read more...
Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business

Ratios

vs
industry
vs
history
PE Ratio 320.66
JNJ's PE Ratio is ranked lower than
98% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. JNJ: 320.66 )
Ranked among companies with meaningful PE Ratio only.
JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.5  Med: 18.38 Max: 368.4
Current: 320.66
10.5
368.4
Forward PE Ratio 16.61
JNJ's Forward PE Ratio is ranked higher than
69% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. JNJ: 16.61 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 320.66
JNJ's PE Ratio without NRI is ranked lower than
97% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. JNJ: 320.66 )
Ranked among companies with meaningful PE Ratio without NRI only.
JNJ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.5  Med: 18.38 Max: 368.4
Current: 320.66
10.5
368.4
Price-to-Owner-Earnings 20.36
JNJ's Price-to-Owner-Earnings is ranked higher than
73% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. JNJ: 20.36 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JNJ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.19  Med: 17.86 Max: 24.95
Current: 20.36
10.19
24.95
PB Ratio 6.01
JNJ's PB Ratio is ranked lower than
79% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. JNJ: 6.01 )
Ranked among companies with meaningful PB Ratio only.
JNJ' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 6.57
Current: 6.01
2.68
6.57
PS Ratio 4.78
JNJ's PS Ratio is ranked lower than
62% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. JNJ: 4.78 )
Ranked among companies with meaningful PS Ratio only.
JNJ' s PS Ratio Range Over the Past 10 Years
Min: 2.16  Med: 3.37 Max: 5.29
Current: 4.78
2.16
5.29
Price-to-Free-Cash-Flow 21.07
JNJ's Price-to-Free-Cash-Flow is ranked higher than
69% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. JNJ: 21.07 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JNJ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.29  Med: 17.54 Max: 24.54
Current: 21.07
10.29
24.54
Price-to-Operating-Cash-Flow 17.49
JNJ's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. JNJ: 17.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JNJ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.99  Med: 14.06 Max: 19.52
Current: 17.49
8.99
19.52
EV-to-EBIT 20.85
JNJ's EV-to-EBIT is ranked lower than
54% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. JNJ: 20.85 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.5 Max: 22.6
Current: 20.85
7.8
22.6
EV-to-EBITDA 15.18
JNJ's EV-to-EBITDA is ranked higher than
55% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. JNJ: 15.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 11.3 Max: 17.3
Current: 15.18
6.7
17.3
EV-to-Revenue 4.87
JNJ's EV-to-Revenue is ranked lower than
61% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. JNJ: 4.87 )
Ranked among companies with meaningful EV-to-Revenue only.
JNJ' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.3 Max: 5.5
Current: 4.87
2.1
5.5
PEG Ratio 49.20
JNJ's PEG Ratio is ranked lower than
98% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. JNJ: 49.20 )
Ranked among companies with meaningful PEG Ratio only.
JNJ' s PEG Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.19 Max: 65.47
Current: 49.2
1.17
65.47
Shiller PE Ratio 29.27
JNJ's Shiller PE Ratio is ranked higher than
58% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. JNJ: 29.27 )
Ranked among companies with meaningful Shiller PE Ratio only.
JNJ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.58  Med: 21.29 Max: 31.35
Current: 29.27
15.58
31.35
Current Ratio 1.65
JNJ's Current Ratio is ranked lower than
66% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. JNJ: 1.65 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.92 Max: 3.08
Current: 1.65
1.2
3.08
Quick Ratio 1.33
JNJ's Quick Ratio is ranked lower than
63% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. JNJ: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.48 Max: 2.68
Current: 1.33
0.94
2.68
Days Inventory 120.79
JNJ's Days Inventory is ranked lower than
51% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. JNJ: 120.79 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 118.92 Max: 137.6
Current: 120.79
100.19
137.6
Days Sales Outstanding 63.84
JNJ's Days Sales Outstanding is ranked higher than
66% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. JNJ: 63.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 58.66 Max: 64.41
Current: 63.84
53.94
64.41
Days Payable 85.90
JNJ's Days Payable is ranked higher than
55% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. JNJ: 85.90 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 85.9  Med: 109.43 Max: 147.94
Current: 85.9
85.9
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.47
JNJ's Dividend Yield % is ranked higher than
72% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. JNJ: 2.47 )
Ranked among companies with meaningful Dividend Yield % only.
JNJ' s Dividend Yield % Range Over the Past 10 Years
Min: 2.25  Med: 2.84 Max: 3.84
Current: 2.47
2.25
3.84
Dividend Payout Ratio 6.58
JNJ's Dividend Payout Ratio is ranked lower than
99% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. JNJ: 6.58 )
Ranked among companies with meaningful Dividend Payout Ratio only.
JNJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.53 Max: 7.06
Current: 6.58
0.39
7.06
3-Year Dividend Growth Rate 6.40
JNJ's 3-Year Dividend Growth Rate is ranked lower than
52% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. JNJ: 6.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
JNJ' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 6.4  Med: 13.4 Max: 17.2
Current: 6.4
6.4
17.2
Forward Dividend Yield % 2.52
JNJ's Forward Dividend Yield % is ranked higher than
71% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. JNJ: 2.52 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.39
JNJ's 5-Year Yield-on-Cost % is ranked higher than
72% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. JNJ: 3.39 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
JNJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.11  Med: 3.93 Max: 5.31
Current: 3.39
3.11
5.31
3-Year Average Share Buyback Ratio 1.20
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. JNJ: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: 0.3 Max: 2.4
Current: 1.2
-4.3
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.91
JNJ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
57% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. JNJ: 1.91 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JNJ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.85  Med: 1.64 Max: 3.51
Current: 1.91
0.85
3.51
Price-to-Intrinsic-Value-DCF (Earnings Based) 29.96
JNJ's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
100% of the 110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. JNJ: 29.96 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
JNJ' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.57  Med: 1.31 Max: 32.64
Current: 29.96
0.57
32.64
Price-to-Median-PS-Value 1.42
JNJ's Price-to-Median-PS-Value is ranked lower than
73% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. JNJ: 1.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JNJ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 1.02 Max: 1.8
Current: 1.42
0.5
1.8
Earnings Yield (Greenblatt) % 4.79
JNJ's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. JNJ: 4.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JNJ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.4  Med: 7.4 Max: 12.9
Current: 4.79
4.4
12.9
Forward Rate of Return (Yacktman) % 8.94
JNJ's Forward Rate of Return (Yacktman) % is ranked higher than
51% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. JNJ: 8.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.9  Med: 13 Max: 17.4
Current: 8.94
1.9
17.4

More Statistics

Revenue (TTM) (Mil) $80,684.00
EPS (TTM) $ 0.44
Beta0.53
Volatility14.84%
52-Week Range $118.62 - 148.32
Shares Outstanding (Mil)2,682.76

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 81,315 83,092 86,826
EBIT (Mil $) 24,626 26,072 27,895
EBITDA (Mil $) 30,251 31,903 33,930
EPS ($) 7.12 8.10 8.68
EPS without NRI ($) 7.12 8.10 8.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.42%
Dividends per Share ($) 3.57 3.77 3.92

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}